Clinical trials
Lung cancer clinical trials
Cancer that begins in the lungs, often linked to smoking but also affecting non-smokers. We’re tracking 2,008 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03647098Recruiting
Lung cancer survival study for adults receiving study treatment
This trial is looking at how well a lung cancer treatment improves survival. It enrolls adults with confirmed lung cancer who can safely take the study medicines and have cancer that can be measured on scans.
Changsha, HunanAges 18 years+ - NCT07405931Recruiting
Managing chemo side effects with phone calls and a smartphone app
This study tests whether checking in by phone or smartphone app can help manage chemotherapy side effects. If you are starting a new chemo for stomach, lung, breast, or colon cancer, this program may support you from home.
BusanAges 19 years+ - NCT07405190RecruitingPhase 2
Ivonescimab with or without chemo for advanced NSCLC
This study tests a new drug, ivonescimab, alone or with chemotherapy (carboplatin and pemetrexed), for people with advanced lung cancer that has specific gene changes and has already been treated with targeted therapy. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT07393490Recruiting
Extra oxygen during lung cancer surgery
This study tests whether giving extra oxygen during surgery helps people who are having part of their lung removed for lung cancer. It may help keep oxygen levels stable while the lung is not being used for breathing.
OsijekAges 18 years+ - NCT07382557Recruiting
Lung cancer screening decision aid for high-risk patients
This study tests a tool to help people decide about lung cancer screening. It is for current or former smokers who have a family history of smoking and lung cancer.
Houston, TexasAges 50–80 - NCT07379476RecruitingPhase 2
Targeted treatment for remaining spots in EGFR lung cancer
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
Hong KongAges 18 years+ - NCT05477979Recruiting
Study how stress affects lung cancer treatment outcomes
This study looks at whether psychological stress changes how well lung cancer treatments work and what the outlook is. You may qualify if you’re about to start (or recently started) certain immunotherapy-based treatments, and you can complete stress and well-being questionnaires.
Changsha, HunanAges 18 years+ - NCT06843707Recruiting
Lung nodule study using blood and tissue metabolism
This trial follows people with lung nodules over time, using blood and tissue samples to look for metabolic changes that may help understand lung cancer better. If you have a lung nodule found on a CT scan and can safely do lung function tests, this study may be a fit.
Guangzhou, GuangdongAges 18–75 - NCT07355205RecruitingPhase 1/Phase 2
Combination immunotherapy for advanced lung cancer
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
St Louis, MissouriAges 18 years+ - NCT07358715Recruiting
Liquid biopsy to improve lung cancer screening
This study tests whether a simple blood test (liquid biopsy) can help find lung cancer earlier in people at high risk. It also includes people already diagnosed with lung cancer to refine the test.
SingaporeAges 21–75 - NCT06849518Recruiting
Blood test to track immunotherapy response in lung cancer
This study is looking at a simple blood test to see if it can help track how well your immunotherapy is working. If you have advanced lung cancer and are getting a standard immunotherapy drug, you may be able to join.
Kingsport, TennesseeAges Any age - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New Haven, ConnecticutAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Sydney, New South WalesAges 18 years+ - NCT07339059RecruitingPhase 2
Maintenance therapy for advanced small cell lung cancer
This trial tests two immunotherapy drugs (sacituzumab govitecan with atezolizumab or durvalumab) as ongoing treatment to keep extensive-stage small cell lung cancer from progressing. It is for people who have already completed initial chemotherapy and immunotherapy without their cancer getting worse.
Detroit, MichiganAges 18 years+ - NCT07328945Recruiting
Personalized treatment for non-small cell lung cancer using a tumor model
This trial tests a new way to choose the best treatment for your lung cancer by creating a model of your tumor in the lab. It may help doctors find the most effective therapy for you.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07323732RecruitingPhase 2
BIO 300 and radiation for lung cancer with lung scarring
This trial tests if adding BIO 300 to chest radiation is safe and helps people who have both non-small cell lung cancer (early stage) and interstitial lung disease (scarring of the lungs). It aims to find better treatment options for this specific group.
Basking Ridge, New JerseyAges 18 years+ - NCT07322341RecruitingPhase 2
Study of SX-682 with atezolizumab for advanced lung cancer
This trial tests a new drug combination (SX-682 plus atezolizumab) for people with advanced non-small cell lung cancer that has grown after standard treatments like immunotherapy and chemotherapy. It aims to see if the combination can help shrink or slow the cancer.
Seattle, WashingtonAges 18 years+ - NCT06730295RecruitingPhase 2
Lung cancer radiation trial shrinking target margins
This trial tests a newer, more precise way of giving radiation for lung cancer tumors that are near the center of the chest. The goal is to see if using a smaller treatment area can reduce side effects while still killing the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07315113RecruitingPhase 1
Study of NXP900 plus osimertinib for EGFR lung cancer
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Calverton, MarylandAges 18 years+ - NCT07309952RecruitingPhase 2
Chemo, immunotherapy and targeted radiation before surgery for advanced lung cancer
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07288034RecruitingPhase 2
Immunotherapy biomarkers for advanced lung cancer
This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.
Goodyear, ArizonaAges 18 years+ - NCT07285434Enrolling by invitationEarly Phase 1
Personalized vaccine for first-line advanced lung cancer
This study tests a personalized vaccine (Microlyvaq™) made just for your tumor, given together with standard chemo and immunotherapy (pembrolizumab). It is for people with advanced non-small cell lung cancer who have not yet started treatment for the advanced stage.
Thessaloniki, MacedoniaAges Any age - NCT07287085Recruiting
Increasing lung cancer screening in emergency patients
This study tests a program to help emergency department patients get screened for lung cancer. If you smoke or used to smoke, the study will see if a text message reminder can help you schedule a screening test.
Rochester, New YorkAges 50–80 - NCT07276789RecruitingPhase 2
Single-dose dye imaging for lung cancer surgery
This trial tests a single dose of a special dye (LS301-IT) that helps surgeons see lung cancer cells more clearly during surgery. It aims to make lung cancer removal more precise and complete.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer?
- Yes. Clin2 currently lists 2,008 recruiting lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.